Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma Histone Deacetylase Inhibitors.pdfVIP

Hindawi Publishing Corporation Lymphoma Volume 2012, Article ID 290685, 10 pages doi:10.1155/2012/290685 Review Article Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors Annabelle L. Rodd,1, 2 Katherine Ververis,1, 2 and Tom C. Karagiannis1, 2 1 Epigenomic Medicine, Baker IDI Heart and Diabetes Institute, The Alfred Medical Research and Education Precinct, Melbourne, VIC 3004, Australia 2 Department of Pathology, The University of Melbourne, Parkville, VIC 3010, Australia Correspondence should be addressed to Tom C. Karagiannis, tom.karagiannis@.au Received 30 May 2012; Accepted 23 June 2012 Academic Editor: Vincent Ribrag Copyright © 2012 Annabelle L. Rodd et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cutaneous T-cell lymphoma is a term that encompasses a spectrum of non-Hodgkin’s T-cell lymphomas with primary manifestations in the skin. It describes a heterogeneous group of neoplasms that are characterised by an accumulation of malignant T cells of the CD4 phenotype that have the propensity to home and accumulate in the skin, lymph nodes, and peripheral blood. ´ The two most common variants of cutaneous T-cell lymphoma include mycosis fungoides and the leukemic variant, the Sezary syndrome. While numerous treatments are available for cutaneous T-cell lymphoma and have shown to have success in those with patch and plaque lesions, for those patients with tumour stage or lymph n